Skip to main content
Erschienen in: Diabetologia 8/2011

01.08.2011 | Article

Biliverdin protects against the deterioration of glucose tolerance in db/db mice

verfasst von: N. Ikeda, T. Inoguchi, N. Sonoda, M. Fujii, R. Takei, E. Hirata, H. Yokomizo, J. Zheng, Y. Maeda, K. Kobayashi, R. Takayanagi

Erschienen in: Diabetologia | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

We have previously shown a negative correlation between serum bilirubin levels and prevalence of type 2 diabetes, suggesting that bilirubin inhibits development of this disease. To confirm this hypothesis, we investigated whether administration of biliverdin, the precursor of bilirubin, protects against the deterioration of glucose tolerance in db/db mice, a rodent model of type 2 diabetes.

Methods

Biliverdin (20 mg/kg daily) was orally administered to 5-week-old db/db mice for 4 weeks. After 4 weeks of treatment, i.p. glucose tolerance and insulin tolerance tests were performed. Insulin content was evaluated by immunostaining and ELISA. Oxidative stress markers (8-hydroxy-2′-deoxyguansosine and dihydroethidium staining) and expression of NADPH oxidase components Pdx1 and Bax were also evaluated in isolated islets.

Results

Treatment with biliverdin partially prevented worsening of hyperglycaemia and glucose intolerance in db/db mice. This effect was accompanied by a significant increase in insulin content and Pdx1 expression, and a significant decrease of apoptosis and Bax expression in pancreatic islets from db/db mice. At the same time, levels of oxidative stress markers and NADPH oxidase component production in islets were normalised. Biliverdin had little effect on HOMA of insulin resistance or insulin resistance evaluated by insulin tolerance tests.

Conclusions/interpretation

Biliverdin may protect against progressive worsening of glucose tolerance in db/db mice, mainly via inhibition of oxidative stress-induced beta cell damage.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Robertson RP (2004) Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 279:42351–42354PubMedCrossRef Robertson RP (2004) Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 279:42351–42354PubMedCrossRef
2.
Zurück zum Zitat Ihara Y, Toyokuni S, Uchida K et al (1999) Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes 48:927–932PubMedCrossRef Ihara Y, Toyokuni S, Uchida K et al (1999) Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes 48:927–932PubMedCrossRef
3.
Zurück zum Zitat Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S (2002) Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 45:85–96PubMedCrossRef Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S (2002) Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 45:85–96PubMedCrossRef
4.
Zurück zum Zitat Houstis N, Rosen ED, Lander ES (2006) Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440:944–948PubMedCrossRef Houstis N, Rosen ED, Lander ES (2006) Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440:944–948PubMedCrossRef
5.
Zurück zum Zitat Paolisso G, Giugliano D (1996) Oxidative stress and insulin action: is there a relationship? Diabetologia 39:357–363PubMedCrossRef Paolisso G, Giugliano D (1996) Oxidative stress and insulin action: is there a relationship? Diabetologia 39:357–363PubMedCrossRef
6.
Zurück zum Zitat Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2003) Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 52:1–8PubMedCrossRef Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2003) Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 52:1–8PubMedCrossRef
7.
Zurück zum Zitat Rudich A, Tirosh A, Potashnik R, Khamaisi M, Bashan N (1999) Lipoic acid protects against oxidative stress induced impairment in insulin stimulation of protein kinase B and glucose transport in 3T3-L1 adipocytes. Diabetologia 42:949–957PubMedCrossRef Rudich A, Tirosh A, Potashnik R, Khamaisi M, Bashan N (1999) Lipoic acid protects against oxidative stress induced impairment in insulin stimulation of protein kinase B and glucose transport in 3T3-L1 adipocytes. Diabetologia 42:949–957PubMedCrossRef
8.
Zurück zum Zitat Schwertner HA, Jackson WG, Tolan G (1994) Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 40:18–23PubMed Schwertner HA, Jackson WG, Tolan G (1994) Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 40:18–23PubMed
9.
Zurück zum Zitat Breimer LH, Wannamethee G, Ebrahim S, Shaper AG (1995) Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 41:1504–1508PubMed Breimer LH, Wannamethee G, Ebrahim S, Shaper AG (1995) Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 41:1504–1508PubMed
10.
Zurück zum Zitat Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR (1996) Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 16:250–255PubMedCrossRef Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR (1996) Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 16:250–255PubMedCrossRef
11.
Zurück zum Zitat Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA (2008) Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999–2004. Am J Med 121:781–788.e1PubMedCrossRef Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA (2008) Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999–2004. Am J Med 121:781–788.e1PubMedCrossRef
12.
Zurück zum Zitat Inoguchi T, Sasaki S, Kobayashi K, Takayanagi R, Yamada T (2007) Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA 298:1398–1400PubMedCrossRef Inoguchi T, Sasaki S, Kobayashi K, Takayanagi R, Yamada T (2007) Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA 298:1398–1400PubMedCrossRef
13.
Zurück zum Zitat Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN (1987) Bilirubin is an antioxidant of possible physiological importance. Science 235:1043–1046PubMedCrossRef Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN (1987) Bilirubin is an antioxidant of possible physiological importance. Science 235:1043–1046PubMedCrossRef
14.
Zurück zum Zitat Ohnaka K, Kono S, Inoguchi T et al (2010) Inverse associations of serum bilirubin with high sensitivity C-reactive protein, glycated hemoglobin, and prevalence of type 2 diabetes in middle-aged and elderly Japanese men and women. Diabetes Res Clin Pract 88:103–110PubMedCrossRef Ohnaka K, Kono S, Inoguchi T et al (2010) Inverse associations of serum bilirubin with high sensitivity C-reactive protein, glycated hemoglobin, and prevalence of type 2 diabetes in middle-aged and elderly Japanese men and women. Diabetes Res Clin Pract 88:103–110PubMedCrossRef
15.
Zurück zum Zitat Han SS, Na KY, Chae DW, Kim YS, Kim S, Chin HJ (2010) High serum bilirubin is associated with the reduced risk of diabetes mellitus and diabetic nephropathy. Tohoku J Exp Med 221:133–140PubMedCrossRef Han SS, Na KY, Chae DW, Kim YS, Kim S, Chin HJ (2010) High serum bilirubin is associated with the reduced risk of diabetes mellitus and diabetic nephropathy. Tohoku J Exp Med 221:133–140PubMedCrossRef
16.
Zurück zum Zitat Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef
17.
Zurück zum Zitat Etoh T, Inoguchi T, Kakimoto M et al (2003) Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia 46:1428–1437PubMedCrossRef Etoh T, Inoguchi T, Kakimoto M et al (2003) Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia 46:1428–1437PubMedCrossRef
18.
Zurück zum Zitat Nakayama M, Inoguchi T, Sonta T et al (2005) Increased expression of NAD(P)H oxidase in islets of animal models of type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochem Biophys Res Commun 332:927–933PubMedCrossRef Nakayama M, Inoguchi T, Sonta T et al (2005) Increased expression of NAD(P)H oxidase in islets of animal models of type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochem Biophys Res Commun 332:927–933PubMedCrossRef
19.
Zurück zum Zitat Fujii M, Inoguchi T, Sasaki S et al (2010) Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD(P)H oxidase. Kidney Int 78:905–919PubMedCrossRef Fujii M, Inoguchi T, Sasaki S et al (2010) Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD(P)H oxidase. Kidney Int 78:905–919PubMedCrossRef
20.
Zurück zum Zitat Andersson A (1978) Isolated mouse pancreatic islets in culture: effects of serum and different culture media on the insulin production of the islets. Diabetologia 14:397–404PubMedCrossRef Andersson A (1978) Isolated mouse pancreatic islets in culture: effects of serum and different culture media on the insulin production of the islets. Diabetologia 14:397–404PubMedCrossRef
21.
Zurück zum Zitat Paz K, Hemi R, LeRoith D et al (1997) A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 272:29911–29918PubMedCrossRef Paz K, Hemi R, LeRoith D et al (1997) A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 272:29911–29918PubMedCrossRef
22.
Zurück zum Zitat Harmon JS, Bogdani M, Parazzoli SD et al (2009) β-Cell-specific overexpression of glutathione peroxidase preserves intranuclear MafA and reverses diabetes in db/db mice. Endocrinology 150:4855–4862PubMedCrossRef Harmon JS, Bogdani M, Parazzoli SD et al (2009) β-Cell-specific overexpression of glutathione peroxidase preserves intranuclear MafA and reverses diabetes in db/db mice. Endocrinology 150:4855–4862PubMedCrossRef
23.
Zurück zum Zitat Kjorholt C, Akerfeldt MC, Biden TJ, Laybutt DR (2005) Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes. Diabetes 54:2755–2763PubMedCrossRef Kjorholt C, Akerfeldt MC, Biden TJ, Laybutt DR (2005) Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes. Diabetes 54:2755–2763PubMedCrossRef
24.
Zurück zum Zitat Stocker R (2004) Antioxidant activities of bile pigments. Antioxid Redox Signal 6:841–849PubMed Stocker R (2004) Antioxidant activities of bile pigments. Antioxid Redox Signal 6:841–849PubMed
25.
Zurück zum Zitat Green K, Brand MD, Murphy MP (2004) Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 53(Suppl 1):S110–S118PubMedCrossRef Green K, Brand MD, Murphy MP (2004) Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 53(Suppl 1):S110–S118PubMedCrossRef
26.
Zurück zum Zitat Inoguchi T, Li P, Umeda F et al (2000) High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49:1939–1945PubMedCrossRef Inoguchi T, Li P, Umeda F et al (2000) High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49:1939–1945PubMedCrossRef
27.
Zurück zum Zitat Kim YK, Lee MS, Son SM et al (2002) Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes 51:522–527PubMedCrossRef Kim YK, Lee MS, Son SM et al (2002) Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes 51:522–527PubMedCrossRef
28.
Zurück zum Zitat Inoguchi T, Sonta T, Tsubouchi H et al (2003) Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 14:S227–S232PubMedCrossRef Inoguchi T, Sonta T, Tsubouchi H et al (2003) Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 14:S227–S232PubMedCrossRef
29.
Zurück zum Zitat Oliveira HR, Verlengia R, Carvalho CR, Britto LR, Curi R, Carpinelli AR (2003) Pancreatic beta-cells express phagocyte-like NAD(P)H oxidase. Diabetes 52:1457–1463PubMedCrossRef Oliveira HR, Verlengia R, Carvalho CR, Britto LR, Curi R, Carpinelli AR (2003) Pancreatic beta-cells express phagocyte-like NAD(P)H oxidase. Diabetes 52:1457–1463PubMedCrossRef
30.
Zurück zum Zitat Guichard C, Moreau R, Pessayre D, Epperson TK, Krause KH (2008) NOX family NADPH oxidases in liver and in pancreatic islets: a role in the metabolic syndrome and diabetes? Biochem Soc Trans 36:920–929PubMedCrossRef Guichard C, Moreau R, Pessayre D, Epperson TK, Krause KH (2008) NOX family NADPH oxidases in liver and in pancreatic islets: a role in the metabolic syndrome and diabetes? Biochem Soc Trans 36:920–929PubMedCrossRef
31.
Zurück zum Zitat Newsholme P, Morgan D, Rebelato E et al (2009) Insights into the critical role of NADPH oxidase(s) in the normal and dysregulated pancreatic beta cell. Diabetologia 52:2489–2498PubMedCrossRef Newsholme P, Morgan D, Rebelato E et al (2009) Insights into the critical role of NADPH oxidase(s) in the normal and dysregulated pancreatic beta cell. Diabetologia 52:2489–2498PubMedCrossRef
32.
Zurück zum Zitat Tsubouchi H, Inoguchi T, Inuo M et al (2005) Sulfonylurea as well as elevated glucose levels stimulate reactive oxygen species production in the pancreatic beta-cell line, MIN6—a role of NAD(P)H oxidase in beta-cells. Biochem Biophys Res Commun 326:60–65PubMedCrossRef Tsubouchi H, Inoguchi T, Inuo M et al (2005) Sulfonylurea as well as elevated glucose levels stimulate reactive oxygen species production in the pancreatic beta-cell line, MIN6—a role of NAD(P)H oxidase in beta-cells. Biochem Biophys Res Commun 326:60–65PubMedCrossRef
Metadaten
Titel
Biliverdin protects against the deterioration of glucose tolerance in db/db mice
verfasst von
N. Ikeda
T. Inoguchi
N. Sonoda
M. Fujii
R. Takei
E. Hirata
H. Yokomizo
J. Zheng
Y. Maeda
K. Kobayashi
R. Takayanagi
Publikationsdatum
01.08.2011
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 8/2011
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2197-2

Weitere Artikel der Ausgabe 8/2011

Diabetologia 8/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.